Table 3.
Estimated cost inputs
| Estimate | SE | Source | |
|---|---|---|---|
| Treatment-related costs | |||
| Monitoring | $95.19 | $4.76 | US Bureau of Labor Statistics27 |
| Treatment switch | $282.98 | $14.15 | Citrome et al19 |
| Relapse-treatment costs | |||
| Inpatient | $32,495.41 | $1,624.77 | Agency for Healthcare Research and Quality54 |
| Outpatient | $657.69 | $32.88 | Park and Kuntz55 |
| Adverse events | |||
| Akathisia | $232.94 | $11.65 | Citrome et al19 |
| EPS | $242.01 | $12.10 | US Bureau of Labor Statistics27 |
| Glucose abnormalities | $75.65 | $3.78 | |
| Lipid abnormalities | $173.39 | $8.67 | |
| Sedation | $282.98 | $14.15 | |
| Weight gain ≥7% | $830.19 | $41.51 | |
| Treatment-acquisition costs (WAC) | |||
| Brexpiprazole | $31.16 | $1.56 | Truven Health Analytics56 |
| 4 mg ($/day) | |||
| Lurasidone | |||
| 40 mg ($/day) | $30.73 | $1.54 | |
| 60 mg ($/day) | $30.73 | $1.54 | |
| 80 mg ($/day) | $30.73 | $1.54 | |
| Cariprazine | |||
| 1.5 mg ($/day) | $33.54 | $1.68 | |
| 3.0 mg ($/day) | $33.54 | $1.68 | |
| 4.5 mg ($/day) | $33.54 | $1.68 | |
| 6.0 mg ($/day) | $33.54 | $1.68 | |
| Composite therapy | |||
| Olanzapine | $18.44 | $0.92 | |
| 10 mg ($/day) | |||
| Risperidone | $23.81 | $1.19 | |
| 4 mg ($/day) | |||
| Quetiapine | $18.75 | $0.94 | |
| 200/300 mg ($/day) | |||
| Ziprasidone | $16.24 | $0.81 | |
| 40/60 mg ($/day) | |||
| Aripiprazole | $42.05 | $2.10 | |
| 30 mg ($/day) |
Notes: All costs reported in 2016 US$.
Abbreviations: EPS, extrapyramidal symptoms; WAC, wholesale-acquisition cost.